Jinekolojik Kanserlerde Genetik Risk ve Testler
Özet
Jinekolojik kanserlerde genetik risk ve testlerin önemi, kalıtsal kanser sendromlarının tespiti ve erken tarama stratejileriyle morbidite ve mortalitenin azaltılmasında kritik bir rol oynamaktadır. İnsan genom projesinin tamamlanmasıyla kişiselleştirilmiş kanser riski yönetimi ve birincil koruma altın standart haline gelmiştir. Katı tümörlerin yaklaşık %10-15'i kalıtımsal mutasyonlar zemininde gelişmekte olup, proto-onkogenler ve tümör baskılayıcı genler karsinogenezde anahtar rol üstlenir. Kalıtsal Meme ve Over Kanseri Sendromu (HBOC), otozomal dominant geçiş gösteren BRCA1 ve BRCA2 germ hattı mutasyonlarıyla karakterizedir ve yaşam boyu over ile meme kanseri riskini önemli ölçüde artırır. Lynch sendromu ise MMR genlerindeki mutasyonlar nedeniyle başta endometrium, kolon ve over olmak üzere çoklu kanser riskine yol açar. Bunun yanı sıra Cowden (PTEN), Peutz-Jeghers (STK11) ve Li-Fraumeni (TP53) gibi diğer sendromlar da spesifik jinekolojik malignite riskleriyle ilişkilidir. Serviks, vulva ve vajen kanserlerinin patogenezinde özellikle yüksek riskli HPV tiplerinin p53 ve RB yollarını inaktive etmesi baskın rol oynarken, endometrium ve over kanserleri moleküler ve histolojik özelliklerine göre tip 1 ve tip 2 olarak alt gruplara ayrılmaktadır. Genetik risk altındaki kadınların saptanmasında birinci basamak hekimlerinin detaylı aile öyküsü alması hayati önem taşır. Risk azaltıcı salpingo-ooferektomi (RRSO) ve histerektomi gibi cerrahi yöntemler ile transvajinal ultrason, serum CA125 takibi ve endometrial örneklemeyi içeren izlem stratejileri, mutasyon taşıyıcılarında kanser gelişimini önlemede temel klinik yaklaşımları oluşturmaktadır.
The importance of genetic risk and testing in gynecological cancers plays a critical role in reducing morbidity and mortality through the detection of hereditary cancer syndromes and early screening strategies. Following the completion of the human genome project, personalized cancer risk management and primary prevention have become the gold standard. Approximately 10-15% of solid tumors develop on the basis of hereditary mutations, with proto-oncogenes and tumor suppressor genes playing a key role in carcinogenesis. Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is characterized by autosomal dominant BRCA1 and BRCA2 germline mutations and significantly increases the lifetime risk of ovarian and breast cancers. Lynch syndrome, caused by mutations in MMR genes, leads to multiple cancer risks, primarily endometrial, colon, and ovarian cancers. Additionally, other syndromes such as Cowden (PTEN), Peutz-Jeghers (STK11), and Li-Fraumeni (TP53) are associated with specific gynecological malignancy risks. While the inactivation of p53 and RB pathways by high-risk HPV types plays a dominant role in the pathogenesis of cervical, vulvar, and vaginal cancers, endometrial and ovarian cancers are categorized into type 1 and type 2 subgroups based on molecular and histological features. Detailed family history taking by primary care physicians is vital in identifying women at genetic risk. Surveillance strategies including transvaginal ultrasound, serum CA125 monitoring, and endometrial sampling, along with surgical methods like risk-reducing salpingo-oophorectomy (RRSO) and hysterectomy, constitute the primary clinical approaches to preventing cancer development in mutation carriers.
Referanslar
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10-17. doi:10.1016/0090-8258(83)90111-7
Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037. doi:10.1073/pnas.1115052108
King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646. doi:10.1126/science.1088759
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies [published correction appears in Am J Hum Genet. 2003 Sep;73(3):709]. Am J Hum Genet. 2003;72(5):1117-1130. doi:10.1086/375033
Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62(3):676-689. doi:10.1086/301749
Lancaster JM, Powell CB, Chen LM, Richardson DL; SGO Clinical Practice Committee. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions [published correction appears in Gynecol Oncol. 2015 Sep;138(3):765]. Gynecol Oncol. 2015;136(1):3-7. doi:10.1016/j.ygyno.2014.09.009
Daly MB, Pilarski R, Berry M, et al. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017. J Natl Compr Canc Netw. 2017;15(1):9-20. doi:10.6004/jnccn.2017.0003
Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012;118(2):493-499. doi:10.1002/cncr.26191
Mersch J, Jackson MA, Park M, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian [published correction appears in Cancer. 2015 Jul 15;121(14):2474-5]. Cancer. 2015;121(2):269-275. doi:10.1002/cncr.29041
Shu CA, Pike MC, Jotwani AR, et al. Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. JAMA Oncol. 2016;2(11):1434-1440. doi:10.1001/jamaoncol.2016.1820
Tiwari AK, Roy HK, Lynch HT. Lynch syndrome in the 21st century: clinical perspectives. QJM. 2016;109(3):151-158. doi:10.1093/qjmed/hcv137
Provenzale D, Gupta S, Ahnen DJ, et al. Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016;14(8):1010-1030. doi:10.6004/jnccn.2016.0108
Barrow E, Hill J, Evans DG. Cancer risk in Lynch Syndrome. Fam Cancer. 2013;12(2):229-240. doi:10.1007/s10689-013-9615-1
Chui MH, Gilks CB, Cooper K, Clarke BA. Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. Adv Anat Pathol. 2013;20(6):378-386. doi:10.1097/PAP.0b013e3182a92cf8
Chui MH, Ryan P, Radigan J, et al. The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. Am J Surg Pathol. 2014;38(9):1173-1181. doi:10.1097/PAS.0000000000000298
Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas [published correction appears in Nat Genet. 2013 Jun;45(6):713. Guarino Almeida, Estrella [corrected to Guarino, Estrella]]. Nat Genet. 2013;45(2):136-144. doi:10.1038/ng.2503
Briggs S, Tomlinson I. Germline and somatic polymerase ε and δ mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol. 2013;230(2):148-153. doi:10.1002/path.4185
Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-332. doi:10.1038/gim.2015.75
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-407. doi:10.1158/1078-0432.CCR-11-2283
van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105(6):1258-1265. doi:10.1038/ajg.2009.725
Resta N, Pierannunzio D, Lenato GM, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. Dig Liver Dis. 2013;45(7):606-611. doi:10.1016/j.dld.2012.12.018
McGarrity TJ, Kulin HE, Zaino RJ. Peutz-Jeghers syndrome. Am J Gastroenterol. 2000;95(3):596-604. doi:10.1111/j.1572-0241.2000.01831.x
Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol. 2011;12(6):559-567. doi:10.1016/S1470-2045(11)70119-X
Kratz CP, Achatz MI, Brugières L, et al. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res. 2017;23(11):e38-e45. doi:10.1158/1078-0432.CCR-17-0408
Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295-1305. doi:10.1016/S1470-2045(16)30249-2
Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-6650.
Cobain EF, Milliron KJ, Merajver SD. Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Semin Oncol. 2016;43(5):528-535. doi:10.1053/j.seminoncol.2016.10.001
Fernandez AF, Esteller M. Viral epigenomes in human tumorigenesis. Oncogene. 2010;29(10):1405-1420. doi:10.1038/onc.2009.517
Saavedra KP, Brebi PM, Roa JC. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics. 2012;4(1):13. Published 2012 Aug 31. doi:10.1186/1868-7083-4-13
Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550-560. doi:10.1038/nrc2886
Carreras R, Alameda F, Mancebo G, et al. A study of Ki-67, c-erbB2 and cyclin D-1 expression in CIN-I, CIN-III and squamous cell carcinoma of the cervix. Histol Histopathol. 2007;22(6):587-592. doi:10.14670/HH-22.587
Ngan HY, Cheung AN, Liu SS, Yip PS, Tsao SW. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. Eur J Cancer. 1999;35(3):481-484. doi:10.1016/s0959-8049(98)00407-9
Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575-580. doi:10.1097/01.AOG.0000154151.14516.f7
Daniels MS. Genetic testing by cancer site: uterus. Cancer J. 2012;18(4):338-342. doi:10.1097/PPO.0b013e3182610cc2
Ring KL, Bruegl AS, Allen BA, et al. Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol. 2016;29(11):1381-1389. doi:10.1038/modpathol.2016.135
Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(1):89-98. doi:10.1097/AOG.0000000000000563
Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16(1):8-13. doi:10.1177/107327480901600102
Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma [published correction appears in Nature. 2013 Aug 8;500(7461):242]. Nature. 2013;497(7447):67-73. doi:10.1038/nature12113
Byron SA, Pollock PM. FGFR2 as a molecular target in endometrial cancer. Future Oncol. 2009;5(1):27-32. doi:10.2217/14796694.5.1.27
Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92(11):924-930. doi:10.1093/jnci/92.11.924
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science. 1998 Jun 5;280(5369):1614-7. doi: 10.1126/science.280.5369.1614. PMID: 9616126.
Bilbao C, Rodríguez G, Ramírez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer. 2006;119(3):563-570. doi:10.1002/ijc.21862
Koh WJ, Abu-Rustum NR, Bean S, et al. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16(2):170-199. doi:10.6004/jnccn.2018.0006
Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814-824.
Doll A, Abal M, Rigau M, et al. Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol. 2008;108(3-5):221-229. doi:10.1016/j.jsbmb.2007.09.020
Luchini C, Veronese N, Solmi M, et al. Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. Oncotarget. 2015;6(36):39088-39097. doi:10.18632/oncotarget.5142
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918-931. doi:10.1016/j.humpath.2011.03.003
Kurman RJ, Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol. 2008;27(2):151-160. doi:10.1097/PGP.0b013e318161e4f5
Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-775. doi:10.1158/1078-0432.CCR-13-2287
Jasin M. Homologous repair of DNA damage and tumorigenesis: the BRCA connection. Oncogene. 2002;21(58):8981-8993. doi:10.1038/sj.onc.1206176
O'Quinn C, Steele P, Ludman MD, Kieser K. Hereditary breast ovarian cancer syndromes in the Maritimes. J Obstet Gynaecol Can. 2010;32(2):155-159. doi:10.1016/S1701-2163(16)34430-9
Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3(2):138-150. doi:10.1016/j.molonc.2009.02.001
Neri A, Rabinerson D, Kaplan B, Levavi H. Hereditary ovarian cancer. Isr J Med Sci. 1995 Feb-Mar;31(2-3):172-5. PMID: 7744589.
Fishman DA, Cohen L, Blank SV, et al. The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol. 2005;192(4):1214-1222. doi:10.1016/j.ajog.2005.01.041
Johnson CC, Kessel B, Riley TL, et al. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol. 2008;110(3):383-389. doi:10.1016/j.ygyno.2008.05.006
Skates SJ, Greene MH, Buys SS, et al. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res. 2017;23(14):3628-3637. doi:10.1158/1078-0432.CCR-15-2750
Renkonen-Sinisalo L, Bützow R, Leminen A, Lehtovirta P, Mecklin JP, Järvinen HJ. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer. 2007;120(4):821-824. doi:10.1002/ijc.22446
Gerritzen LH, Hoogerbrugge N, Oei AL, et al. Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. Fam Cancer. 2009;8(4):391-397. doi:10.1007/s10689-009-9252-x
